Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FDPS | P14324 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL10894755 | 0.87 | TP53 (0.52) | TP53CA1CA2PPARAEPHX1 | |
| SCHEMBL16586781 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL16586496 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL16586628 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL16586471 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL16586470 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL16586448 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL16586437 | 0.82 | TP53 (0.38) | TP53CA1CA2PPARAEPHX2 | |
| SCHEMBL31189062 | 0.82 | TP53 (0.43) | TP53CA1CA2PPARAEPHX1 | |
| SCHEMBL31189067 | 0.82 | TP53 (0.43) | TP53CA1CA2PPARAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | TP53 2836/4885CA1 445/4885CA2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.